Recently, a large prospective study for AML with germline DDX41 variants revealed that the response to conventional chemotherapy for the patients is relatively good, although relapse at 3 years post-treatment is comparable to that of patients with wild-type DDX41 (18). The gene discussed is DDX41; the disease is acute myeloid leukemia.